Home > Opioid antagonists with minimal sedation for opioid withdrawal.

Gowing, Linda and Ali, Robert and White, Jason M [The Cochrane Library] . (2017) Opioid antagonists with minimal sedation for opioid withdrawal. John Wiley & Sons, Ltd. Cochrane Database of Systematic Reviews (6) DOI: 10.1002/14651858.CD002021.pub4

URL: http://onlinelibrary.wiley.com/doi/10.1002/1465185...

Key results:
We are uncertain whether peak withdrawal induced by opioid antagonists plus clonidine or lofexidine is more severe than withdrawal managed with clonidine or lofexidine alone, or whether the average severity over the withdrawal period is less, as the certainty of the evidence is very low.

Clinicians should warn people of the possibility of delirium in the first day of administration of naltrexone, particularly with higher doses (> 25 mg). People should also know that withdrawal will be moderately severe and that symptoms such as muscle aches, vomiting and diarrhoea, and insomnia are likely to persist despite medication.


Item Type:Evidence resource
Publication Type:Review
Drug Type:Opioid
Intervention Type:AOD disorder drug therapy
Source:The Cochrane Library
Date:May 2017
Publisher:John Wiley & Sons, Ltd
Number:6
EndNote:View
Accession Number:HRB (Electronic Only)
Subjects:B Substances > Opioids (opiates)
B Substances > Opioids (opiates) > Opioid product > Naltrexone
G Health and disease > Substance use disorder > Drug use > Drug withdrawal syndrome
HJ Treatment method > Substance disorder treatment method > Substance disorder drug therapy
HJ Treatment method > Substance disorder treatment method > Substance replacement method (substitution)
HJ Treatment method > Treatment outcome
J Health care, prevention and rehabilitation > Health care administration > Health care quality control

Repository Staff Only: item control page